Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

Ahmet Sezer; Saadettin Kilickap; Mahmut Gümüş; Igor Bondarenko; Mustafa Özgüroğlu; Miranda Gogishvili; Haci M Turk; Irfan Cicin; Dmitry Bentsion; Oleg Gladkov; Philip Clingan; Virote Sriuranpong; Naiyer Rizvi; Bo Gao; Siyu Li; Sue Lee; Kristina McGuire; Chieh-I Chen; Tamta Makharadze; Semra Paydas; Marina Nechaeva; Frank Seebach; David M Weinreich; George D Yancopoulos; Giuseppe Gullo; Israel Lowy; Petra Rietschel

doi:10.1016/s0140-6736(21)00228-2

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

The Lancet ◽

10.1016/s0140-6736(21)00228-2 ◽

2021 ◽

Vol 397 (10274) ◽

pp. 592-604 ◽

Cited By ~ 3

Author(s):

Ahmet Sezer ◽

Saadettin Kilickap ◽

Mahmut Gümüş ◽

Igor Bondarenko ◽

Mustafa Özgüroğlu ◽

...

Keyword(s):

Lung Cancer ◽

Controlled Trial ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Randomised Controlled ◽

First Line Treatment

Download Full-text

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

The Lancet Oncology ◽

10.1016/s1470-2045(16)30033-x ◽

2016 ◽

Vol 17 (5) ◽

pp. 577-589 ◽

Cited By ~ 437

Author(s):

Keunchil Park ◽

Eng-Huat Tan ◽

Ken O'Byrne ◽

Li Zhang ◽

Michael Boyer ◽

...

Keyword(s):

Lung Cancer ◽

Egfr Mutation ◽

Controlled Trial ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Randomised Controlled ◽

First Line Treatment

Download Full-text

First Line Treatment with Erlotinib Plus Bevacizumab or with Erlotinib Alone in Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations (NEJ026): An Open-Label, Randomized, Multicenter, Phase 3 Study

SSRN Electronic Journal ◽

10.2139/ssrn.3271416 ◽

2018 ◽

Author(s):

Haruhiro Saito ◽

Tatsuro Fukuhara ◽

Naoki Furuya ◽

Kana Watanabe ◽

Shunichi Sugawara ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell ◽

Egfr Mutations ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Multicenter Phase ◽

First Line Treatment

Download Full-text

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

The Lancet Oncology ◽

10.1016/s1470-2045(11)70184-x ◽

2011 ◽

Vol 12 (8) ◽

pp. 735-742 ◽

Cited By ~ 2256

Author(s):

Caicun Zhou ◽

Yi-Long Wu ◽

Gongyan Chen ◽

Jifeng Feng ◽

Xiao-Qing Liu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Egfr Mutation ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

First Line Treatment

Download Full-text

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

The Lancet ◽

10.1016/s0140-6736(19)32222-6 ◽

2019 ◽

Vol 394 (10212) ◽

pp. 1929-1939 ◽

Cited By ~ 172

Author(s):

Luis Paz-Ares ◽

Mikhail Dvorkin ◽

Yuanbin Chen ◽

Niels Reinmuth ◽

Katsuyuki Hotta ◽

...

Keyword(s):

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Extensive Stage ◽

Randomised Controlled ◽

First Line Treatment

Download Full-text

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30608-3 ◽

2017 ◽

Vol 18 (11) ◽

pp. 1454-1466 ◽

Cited By ~ 300

Author(s):

Yi-Long Wu ◽

Ying Cheng ◽

Xiangdong Zhou ◽

Ki Hyeong Lee ◽

Kazuhiko Nakagawa ◽

...

Keyword(s):

Lung Cancer ◽

Egfr Mutation ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

Faculty Opinions recommendation of Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.12351956.13537054 ◽

2011 ◽

Author(s):

Thomas Stinchcombe

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Egfr Mutation ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

First Line Treatment

Download Full-text

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(20)30539-8 ◽

2021 ◽

Vol 22 (1) ◽

pp. 51-65 ◽

Cited By ~ 1

Author(s):

Jonathan W Goldman ◽

Mikhail Dvorkin ◽

Yuanbin Chen ◽

Niels Reinmuth ◽

Katsuyuki Hotta ◽

...

Keyword(s):

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Extensive Stage ◽

Randomised Controlled ◽

First Line Treatment

Download Full-text

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(13)70604-1 ◽

2014 ◽

Vol 15 (2) ◽

pp. 213-222 ◽

Cited By ~ 979

Author(s):

Yi-Long Wu ◽

Caicun Zhou ◽

Cheng-Ping Hu ◽

Jifeng Feng ◽

Shun Lu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell ◽

Egfr Mutations ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Asian Patients ◽

First Line Treatment

Download Full-text

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(19)30167-6 ◽

2019 ◽

Vol 20 (7) ◽

pp. 924-937 ◽

Cited By ~ 202

Author(s):

Howard West ◽

Michael McCleod ◽

Maen Hussein ◽

Alessandro Morabito ◽

Achim Rittmeyer ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(11)70393-x ◽

2012 ◽

Vol 13 (3) ◽

pp. 239-246 ◽

Cited By ~ 3047

Author(s):

Rafael Rosell ◽

Enric Carcereny ◽

Radj Gervais ◽

Alain Vergnenegre ◽

Bartomeu Massuti ◽

...

Keyword(s):

Lung Cancer ◽

Egfr Mutation ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Standard Chemotherapy ◽

Open Label ◽

Phase 3 ◽

First Line Treatment

Download Full-text